Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2084296 | 0.98 | ALDH1A1 (0.42) | ALDH1A1MAPTLMNABLMHDAC9 | |
| SCHEMBL9679498 | 0.76 | CES2 (0.44) | ALDH1A1MAPTLMNAGAAPOLB | |
| SCHEMBL6773172 | 0.75 | BRD4 (0.42) | ALDH1A1MAPTGAAPOLB | |
| SCHEMBL5837737 | 0.75 | BRD4 (0.42) | ALDH1A1MAPTGAAPOLB | |
| SCHEMBL3733923 | 0.75 | HDAC9 (0.38) | MAPTHDAC9GAA | |
| SCHEMBL1786936 | 0.72 | HDAC9 (0.44) | LMNAHDAC9POLBL3MBTL1 | |
| SCHEMBL1011335 | 0.72 | ALDH1A1 (0.52) | ALDH1A1MAPTGAA | |
| SCHEMBL29789782 | 0.72 | ALDH1A1 (0.52) | ALDH1A1MAPTGAA | |
| SCHEMBL9681676 | 0.72 | PDE4A (0.47) | ALDH1A1MAPTGAAL3MBTL1TSHR | |
| SCHEMBL10886045 | 0.72 | RAB9A (0.34) | GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7291619-B2 | Melanocortin receptor agonists | ELI LILLY AND COMPANY (US) | 2007-11-06 | — | — | US | disclosed |
| US-7169777-B2 | Melanocortin receptor agonists | ELI LILLY AND COMPANY (US) | 2007-01-30 | — | — | US | disclosed |
| EP-1368340-B1 | PIPERAZINE DERIVATIVES AS MELANOCORTIN RECEPTOR AGONISTS | LILLY CO ELI (US) | 2005-08-10 | — | — | EP | disclosed |
| US-20040092507-A1 | Melanocortin receptor agonists | ELI LILLY AND COMPANY | 2004-05-13 | — | — | US | disclosed |
| US-6548667-B2 | For prevention and treatment of diseases caused by overexpression and overactivation of matrix metalloproteinase | SAMSUNG ELECTRONICS CO. LTD. (KR) | 2003-04-15 | — | — | US | disclosed |
| US-20020169314-A1 | Sulfonamide derivative as a matrix metalloproteinase inhibitor | SAMSUNG ELECTRONICS CO. LTD. (KR) | 2002-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092507-A1 | Melanocortin receptor agonists | MC1R, MC4R, MC5R | ALDH1A1 1055/4885MAPT 2356/4885LMNA 4634/4885 |
| US-20020169314-A1 | Sulfonamide derivative as a matrix metalloproteinase inhibitor | MMP9, MMP3, MMP14 | ALDH1A1 311/4885MAPT 4046/4885LMNA 1839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.